| Patents for C07K 14 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof (291,526) |
|---|
| 01/27/2011 | US20110020865 Gene Expression Technique |
| 01/27/2011 | US20110020848 Method for detection of pneumococcus |
| 01/27/2011 | US20110020846 Oral cancer biomarker and inspection method using the same |
| 01/27/2011 | US20110020807 Methylated CpG Island Amplification (MCA) |
| 01/27/2011 | US20110020802 Nucleic acids, methods and kits for the diagnosis of dyt6 primary torsion dystonia |
| 01/27/2011 | US20110020800 Characterization of BBK07 antigen of Borrelia burgdorferi and methods of use |
| 01/27/2011 | US20110020798 Novel italy, LOR-2, strife, trash, BDSF, LRSG, and STMST protein and nucleic acid molecules and uses therefor |
| 01/27/2011 | US20110020784 Red fluorescent proteins with enhanced bacterial expression, increased brightness and reduced aggregation |
| 01/27/2011 | US20110020649 Method for immobilization, physiologically active substance-immobilized carrier, carrier for immobilization, carrier, and process for producing carrier |
| 01/27/2011 | US20110020471 Erythrocyte atp-release modulators |
| 01/27/2011 | US20110020435 Stabilizing alkylglycoside compositions and methods thereof |
| 01/27/2011 | US20110020431 Antitumor effect of mutant bik |
| 01/27/2011 | US20110020411 Factor replacement therapy |
| 01/27/2011 | US20110020405 Vaccine comprising a ribosomal protein extract (rpe) and optionally a th1-promoting adjuvant |
| 01/27/2011 | US20110020402 Method For Identification, Isolation And Production Of Antigens To A Specific Pathogen |
| 01/27/2011 | US20110020398 Novel peptide compositions and their use in particular in the preparation of pharmaceutical compositions active against the hepatitis C virus |
| 01/27/2011 | US20110020397 Hydrophobic modified pres-derived peptides of hepatitis b virus (hbv) and their use as hbv and hdv entry inhibitors |
| 01/27/2011 | US20110020396 HIV Envelope-CD4 Complexes and Hybrids |
| 01/27/2011 | US20110020394 Pcv2 orf2 virus like particle with foreign amino acid insertion |
| 01/27/2011 | US20110020387 Malaria vaccine |
| 01/27/2011 | US20110020385 COMBINATIONS OF PNEUMOCOCCAL RrgB CLADES |
| 01/27/2011 | US20110020384 Therapeutic tb vaccine |
| 01/27/2011 | US20110020383 Novel genes and proteins of brachyspira hyodysenteriae and uses thereof |
| 01/27/2011 | US20110020382 Nucleic acid and amino acid sequences relating to staphylococcus epidermidis for diagnostics and therapeutics |
| 01/27/2011 | US20110020378 Self-assembling peptide nanoparticles useful as vaccines |
| 01/27/2011 | US20110020375 Stromal cell-derived factor-1 polypeptides, polynucleotides, modulators thereof and methods of use |
| 01/27/2011 | US20110020372 Follistatin domain containing proteins |
| 01/27/2011 | US20110020355 Treatment and prevention of gardnerella vaginalis infections |
| 01/27/2011 | US20110020354 G-protein coupled receptor ligands and methods |
| 01/27/2011 | US20110020352 Endogenous retroviruses up-regulated in prostate cancer |
| 01/27/2011 | US20110020351 Novel polypeptide esdn, polynucleotides encoding the polypeptide, and utility of the polypeptide |
| 01/27/2011 | US20110020350 Contraceptives Based on SP22 and SP22 Antibodies |
| 01/27/2011 | US20110020346 Anti-vegf antibodies |
| 01/27/2011 | US20110020341 Novel multidrug resistance-associated polypeptide |
| 01/27/2011 | US20110020340 Antibody-light fusion products for cancer therapeutics |
| 01/27/2011 | US20110020335 Treatment of Cancers Expressing p95 ErbB2 |
| 01/27/2011 | US20110020330 Antibody inhibitors of gdf-8 and uses thereof |
| 01/27/2011 | US20110020327 Purification of proteins |
| 01/27/2011 | US20110020321 Methods and compositions for using mhc class ii invariant chain polypeptide as a receptor for macrophage migration inhibitory factor |
| 01/27/2011 | US20110020298 Collagen-binding synthetic peptidoglycans, preparation, and methods of use |
| 01/27/2011 | US20110020289 Novel mycovirus, attenuated strain of phytopathogenic fungus, plant disease controlling agent, method of producing mycovirus, method of attenuating phytopathogenic fungus and method of controlling plant disease |
| 01/27/2011 | US20110020288 Reoviruses Having Modified Sequences |
| 01/27/2011 | US20110020273 Bispecific Immunocytokine Dock-and-Lock (DNL) Complexes and Therapeutic Use Thereof |
| 01/27/2011 | US20110020268 Agent comprising g-csf for treatment of traumatic peripheral nerve injury and method for treating traumatic peripheral nerve injury with the same |
| 01/27/2011 | US20110020267 Tweak receptor |
| 01/27/2011 | US20110020266 G-CSF Conjugates |
| 01/27/2011 | US20110020229 Multi-Component Biological Transport Systems |
| 01/27/2011 | US20110020223 Polypeptides having affinity for her2 |
| 01/27/2011 | US20110018866 Structure of the farnesoid x receptor ligand binding domain and methods of use therefor |
| 01/27/2011 | US20110017943 Use of hydrophobins to prevent ice from forming on surfaces |
| 01/27/2011 | CA2768938A1 Lentiviral vectors pseudotyped with a sindbis virus envelope glycoprotein |
| 01/27/2011 | CA2768621A1 Analogues of insulin-like growth factor-1 (igf-1) having amino acid substitution at position 59 |
| 01/27/2011 | CA2768571A1 The use of dimerization domain component stacks to modulate plant architecture |
| 01/27/2011 | CA2768398A1 Dendritic cell vaccines for asparaginyl-.beta.-hydroxylase expressing tumors |
| 01/27/2011 | CA2768386A1 Compounds which inhibit muscle contraction |
| 01/27/2011 | CA2768206A1 Compositions and methods of use for post-radiation protection |
| 01/27/2011 | CA2768125A1 Plastid transit peptides derived from lower photosynthetic eukaryotes and methods |
| 01/27/2011 | CA2768042A1 Raf dimers and uses thereof |
| 01/27/2011 | CA2767810A1 Methods for removal of microcystins and isolation of phycocyanin from cyanobacteria |
| 01/27/2011 | CA2765313A1 Methods and compositions for improving sugar transport, mixed sugar fermentation, and production of biofuels |
| 01/27/2011 | CA2708848A1 Method for preparing porous collagen matrices |
| 01/27/2011 | CA2708844A1 Preparation of high purity collagen |
| 01/26/2011 | EP2278024A1 Epitope cluster from NY-ESO-1 for the induction of anti-tumor immunogenicity |
| 01/26/2011 | EP2278023A1 Epitope cluster from Melan-A/MART-1 for the induction of anti-tumor immunogenicity |
| 01/26/2011 | EP2278022A2 Expression vectors, transfection systems, and method of use thereof |
| 01/26/2011 | EP2278021A2 Expression vectors, transfection systems, and method of use thereof |
| 01/26/2011 | EP2278019A1 Nucleotide sequences mediating plant male fertility and method of using same |
| 01/26/2011 | EP2278016A1 Promoter sequences derived from Fusarium Venenatum and uses thereof |
| 01/26/2011 | EP2278013A1 Streptococcus pneumoniae open reading frames encoding polypeptide antigens and uses thereof |
| 01/26/2011 | EP2278012A2 Avirulent, immunogenic flavivirus chimeras |
| 01/26/2011 | EP2278011A2 Neisseria meningitidis antigens |
| 01/26/2011 | EP2278010A1 Streptococcus pneumoniae proteins and nucleic acids |
| 01/26/2011 | EP2278009A1 Streptococcus pneumoniae proteins and nucleic acids |
| 01/26/2011 | EP2278008A2 Streptococcus pneumoniae proteins and nucleic acids |
| 01/26/2011 | EP2278007A1 Conserved neisserial antigens |
| 01/26/2011 | EP2278006A2 Neisserial antigens |
| 01/26/2011 | EP2277918A2 Mhc class I and II peptide antigens derived from tumour antigen 5t4 |
| 01/26/2011 | EP2277917A2 B7-H3L cell surface target and a family of antibodies recognizing that target |
| 01/26/2011 | EP2277912A2 Isolation of plasma or serum proteins |
| 01/26/2011 | EP2277911A1 Treatment of viral infections Apo E |
| 01/26/2011 | EP2277910A1 Albumin fusion proteins |
| 01/26/2011 | EP2277909A1 Glucagon-like peptide-2 derivatives and their therapeutic use |
| 01/26/2011 | EP2277908A2 IL-17A/F heterologous polypeptides, antibodies and therapeutic uses thereof |
| 01/26/2011 | EP2277907A2 Differential in tumour gene products and use of same |
| 01/26/2011 | EP2277906A2 Differential in tumour gene products and use of same |
| 01/26/2011 | EP2277905A2 Differential in tumour gene products and use of same |
| 01/26/2011 | EP2277904A2 Differential in tumour gene products and use of same |
| 01/26/2011 | EP2277903A2 Differential in tumour gene products and use of same |
| 01/26/2011 | EP2277902A2 Differential in tumour gene products and use of same |
| 01/26/2011 | EP2277901A2 Differential in tumour gene products and use of same |
| 01/26/2011 | EP2277900A1 Metastin derivative and use thereof |
| 01/26/2011 | EP2277899A2 Antimicrobial peptides |
| 01/26/2011 | EP2277898A2 Rapamycin analogues |
| 01/26/2011 | EP2277897A1 Streptococcus pneumoniae open reading frames encoding polypeptide antigens and uses thereof |
| 01/26/2011 | EP2277896A1 Nucleic acids and proteins from streptococcus groups A & B |
| 01/26/2011 | EP2277895A1 Nucleic acids and proteins from streptococcus groups A & B |
| 01/26/2011 | EP2277894A1 Nucleic acids and proteins from streptococcus groups A & B |
| 01/26/2011 | EP2277893A2 Compounds and methods for treatment and diagnosis of chlamydial infection |
| 01/26/2011 | EP2277892A2 Compounds and methods for treatment and diagnosis of chlamydial infection |
| 01/26/2011 | EP2277891A1 CRYSTAL STRUCTURE OF THE INFLUENZA VIRUS POLYMERASE PAc-PB1n COMPLEX AND USES THEREOF |